Alnylam Pharmaceuticals
ALNY
#1072
Rank
S$28.45 B
Marketcap
S$212.46
Share price
5.36%
Change (1 day)
-64.47%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of September 2026 : S$4.61 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has S$4.61 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2026)

Cash on Hand by year

Year Cash on Hand Change
2025-12-31S$3.73 B1.96%
2024-12-31S$3.66 B13.68%
2023-12-31S$3.22 B9.61%
2022-12-31S$2.93 B-10.74%
2021-12-31S$3.29 B32.78%
2020-12-31S$2.47 B19.73%
2019-12-31S$2.07 B39.83%
2018-12-31S$1.48 B-34.5%
2017-12-31S$2.26 B149.26%
2016-12-31S$0.90 B-40.65%
2015-12-31S$1.52 B66.03%
2014-12-31S$0.92 B195.51%
2013-12-31S$0.31 B107.42%
2012-12-31S$0.15 B-20.79%
2011-12-31S$0.18 B-36.86%
2010-12-31S$0.30 B-23.99%
2009-12-31S$0.39 B-35.81%
2008-12-31S$0.61 B9.69%
2007-12-31S$0.56 B68.43%
2006-12-31S$0.33 B150.1%
2005-12-31S$0.13 B77.32%
2004-12-31S$75.11 M90.63%
2003-12-31S$39.4 M46.73%
2002-12-31S$26.85 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Novartis
NVS
S$11.55 B 150.19%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
S$9.32 B 102.03%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
S$10.29 B 122.86%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
S$1.01 B-78.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
S$84.14 M-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
S$0.38 B-91.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
S$4.70 B 1.89%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
S$2.06 B-55.34%๐Ÿ‡บ๐Ÿ‡ธ USA